Randomized Phase II Study To Assess The Role Of Nivolumab As Single Agent To Eliminate Minimal Residual Disease And Maintain Remission In Acute Myelogenous Leukemia (AML) Patients After Chemotherapy
This randomized phase II trial studies how well nivolumab works in eliminating any remaining
cancer cells and preventing cancer from returning in patients with acute myeloid leukemia
that had a decrease in or disappearance of signs and symptoms of cancer after receiving
chemotherapy. Monoclonal antibodies, such as nivolumab, may block cancer growth in different
ways by targeting certain cells.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.